Pharmaceuticals, Biotechnology and Life Sciences
Swedish Cyxone has submitted an application to the CEC in Poland for permission to start a clinical phase IIb trial with Cyxone’s drug candidate Rabeximod in RA , marking the first regulatory step towards the initiation of the study.
Treatment emergent adverse events Grade 3 or higher were reported by 20 of 32 patients from the 50/60 dose pooled patient analysis; no patient reported Grade 3 or higher fatigue or peripheral neuropathy (primary endpoint) –
Tilray expands European leadership team
Strives to Change the Cancer Treatment Model in Hong Kong Ready to Tap Tremendous Opportunities in Greater Bay Area HONG…
The award-winner of the 2019 Hansen Family Award is Professor Edith Heard. The Board of Trustees of the Bayer Science & Education Foundation and the Scientific Committee for this award have presented her with one of Germany’s most prestigious scientific accolades including a prize money of EUR 75,000.
– ULTOMIRIS has the potential to become the new standard of care for both complement inhibitor-naïve patients and patients switching from SOLIRIS® (eculizumab) –
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), the global biotechnology leader in rare diseases, will present research covering a broad range of rare bleeding disorders at the 27th Annual International Society on Thrombosis and Haemostasis Congress
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial, a therapeutic equivalent generic version of Hemabate® injection, 250 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA).
OSS, Netherlands–(BUSINESS WIRE)–http://www.citryll.com/ announced today the first closing of a targeted € 15 million investment round, funded by ModiQuest B.V.,…
Eligible PEA PME) (Paris:ALCOR), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, announces that they have entered into an exclusive negotiation with SANOFI, a worldwide leader within the pharmaceutical industry, aimed at introducing their Mallya connected device into SANOFI’s integrated diabetes care platform.